--- title: Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer nct_id: NCT00004151 overall_status: COMPLETED phase: PHASE2 sponsor: European Organisation for Research and Treatment of Cancer - EORTC study_type: INTERVENTIONAL primary_condition: Lung Cancer countries: Austria, Denmark, France, Germany, Italy, Spain canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00004151.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00004151" ct_last_update_post_date: 2012-09-24 last_seen_at: "2026-05-12T06:24:11.485Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer **Official Title:** Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer **NCT ID:** [NCT00004151](https://clinicaltrials.gov/study/NCT00004151) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 15 - **Lead Sponsor:** European Organisation for Research and Treatment of Cancer - EORTC - **Conditions:** Lung Cancer - **Start Date:** 1999-09 - **CT.gov Last Update:** 2012-09-24 ## Brief Summary RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery. ## Detailed Description OBJECTIVES: I. Determine the effect of acridine carboxamide on objective response, response rate, and duration of response in patients with unresectable, locally advanced, progressive or metastatic non-small cell lung cancer. II. Determine the toxicities and pharmacokinetics of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive acridine carboxamide IV over 24 hours for 5 days. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression or commencement of another treatment. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` DISEASE CHARACTERISTICS: Histologically proven unresectable, locally advanced, progressive or metastatic non-small cell lung cancer Not amenable to curative surgery or radiotherapy No prior first line chemotherapy for metastatic or advanced disease At least 1 bidimensionally measurable target lesion by CT scan No symptomatic brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: WBC greater than 3,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 times upper limit of normal (ULN) SGOT, SGPT, and alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases present) Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No ischemic heart disease within the past 6 months Normal 12 lead ECG Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No other prior or concurrent malignancy except cone biopsied carcinoma of the cervix or adequately treated basal or squamous cell skin cancer No unstable systemic disease or active uncontrolled infection No psychological, familial, sociological, or geographical condition that could preclude compliance PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: At least 2 weeks since prior major surgery Other: No other concurrent anticancer agents No other concurrent investigational therapy ``` ## Interventions - **acridine carboxamide** (DRUG) ## Locations (8) - Kaiser Franz Josef Hospital, Vienna, Austria - Rigshospitalet, Copenhagen, Denmark - Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France - CHU de la Timone, Marseille, France - Haemato-Onkologische Praxis und Tagesklinik, Munich, Germany - Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy - Istituti Fisioterapici Ospitalieri - Roma, Rome, Italy - Hospital Universitario 12 de Octubre, Madrid, Spain ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.kaiser franz josef hospital|vienna||austria` — added _(2026-05-12)_ - `locations.rigshospitalet|copenhagen||denmark` — added _(2026-05-12)_ - `locations.centre de lute contre le cancer,georges-francois leclerc|dijon||france` — added _(2026-05-12)_ - `locations.chu de la timone|marseille||france` — added _(2026-05-12)_ - `locations.haemato-onkologische praxis und tagesklinik|munich||germany` — added _(2026-05-12)_ - `locations.istituto nazionale per lo studio e la cura dei tumori|naples||italy` — added _(2026-05-12)_ - `locations.istituti fisioterapici ospitalieri - roma|rome||italy` — added _(2026-05-12)_ - `locations.hospital universitario 12 de octubre|madrid||spain` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00004151.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00004151* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*